Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Crinetics Pharmaceuticals, Inc. | Chief Development Officer | Common Stock | 177K | $6.66M | $37.65 | Mar 1, 2022 | Direct |
Crinetics Pharmaceuticals, Inc. | Chief Development Officer | Common Stock (right to buy) | 65.4K | $1.12M | $17.12 | Feb 28, 2022 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
CRNX | Crinetics Pharmaceuticals, Inc. | Feb 28, 2022 | 3 | $179K | 4 | Mar 2, 2022 | Chief Development Officer |
CRNX | Crinetics Pharmaceuticals, Inc. | Feb 7, 2022 | 1 | -$239K | 4 | Feb 9, 2022 | Chief Development Officer |
CRNX | Crinetics Pharmaceuticals, Inc. | Dec 31, 2021 | 1 | $8.65K | 5 | Feb 4, 2022 | Chief Development Officer |
CRNX | Crinetics Pharmaceuticals, Inc. | Oct 28, 2021 | 2 | $77.7K | 4 | Nov 1, 2021 | Chief Development Officer |